Biofarm SA

As of June 30, 2026, Biofarm SA carries a market capitalization of 1.35B, placing it among publicly traded companies globally. Its enterprise value stands at 1.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Biofarm SA has 985.37M shares outstanding.

As of June 30, 2026, Biofarm SA trades at a trailing price-to-earnings ratio of 17.25. The price-to-sales ratio is 4.59, and the price-to-book ratio stands at 3.42.

As of June 30, 2026, Biofarm SA trades at an EV/EBITDA multiple of 11.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.76 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biofarm SA trades at an EV/FCF ratio of 21.57, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.14B versus a market cap of 1.35B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Biofarm SA maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Biofarm SA posted a return on equity (ROE) of 17.55, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.53 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.11, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.51, useful for judging operating efficiency across full business cycles. The company generates approximately 770,298.23 in revenue per employee across its workforce of 382.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.62 indicates how many times Biofarm SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Biofarm SA recorded 10.43M in income tax expense. That works out to an effective tax rate of 11.76, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 88.68M, leaving 78.25M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 24, 2026, Biofarm SA's stock has gained approximately 64.27% over the past 52 weeks. The 50-day moving average sits at 1.37, while the 200-day moving average is 1.19.

Over the twelve months ended June 30, 2026, Biofarm SA generated 294.25M in revenue and converted that into 78.25M in net income, yielding earnings per share of 0.08. EBITDA reached 97.72M, while operating income came in at 76.39M.

As of June 30, 2026, Biofarm SA holds 208.02M in cash and equivalents against 1.13M in total debt, resulting in a net debt position of -206.88M. Total book value stands at 395.18M, with working capital of 187.83M providing operational flexibility.

Biofarm SA produced 71.03M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18.04M in capital expenditures, free cash flow totaled 52.99M - equivalent to 0.05 per share.

Over the twelve months ended June 30, 2026, Biofarm SA posted a gross margin of 86.87, reflecting its pricing power and cost economics. The operating margin of 25.96 and net profit margin of 26.59 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Biofarm SA paid dividends of 0.07 per share. The dividend payout ratio of 87.48 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.93, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Biofarm SA shareholders.

Biofarm SA's most recent stock split took place on April 30, 2008 with a 25:28 split ratio.

As of June 30, 2026, Biofarm SA has an Altman Z-Score of 5.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.